Healios K.K (TYO:4593) has launched a medical materials and equipment division to secure a steady supply of culture supernatant and expand its business, according to a Friday filing on the Tokyo Stock Exchange.
The division will manage production, quality control, and regulatory compliance, and support market research and customer engagement.
This follows Healios' partnership with AND medical group to supply culture supernatant for new treatments and cosmetics. Healios is also seeking conditional approval in Japan for its MultiStem therapy targeting acute respiratory distress syndrome (ARDS).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.